Precision treatment for advanced bile duct cancer
Part of Cancer clinical trials.
This trial is testing treatments that are customized to the specific genetic changes in your bile duct or gallbladder cancer. The goal is to find a drug that targets your tumor's unique mutation, which may help control the cancer better than a one-size-fits-all approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced bile duct or gallbladder cancer that cannot be removed with surgery.
- Your tumor has at least one specific gene change (such as FGFR2, IDH1/2, HER2, BRAF, KRAS, and others) that can be targeted by a drug.
- You feel well enough to carry out daily activities, with no or only mild limitations.
- You have at least one tumor that can be measured on a scan (at least 1 cm in size).
- Your liver, blood counts, and heart function are within acceptable levels, and you are expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This study tests a new treatment combination for advanced bile duct or gallbladder cancer that has not been treated before. It aims to slow cancer growth and may be a good option if you have not had prior therapy for your cancer.
This trial tests a combination of freezing the tumor (cryoablation), an experimental immunotherapy (SHR-1701), and a targeted therapy pill (famitinib) for people with advanced bile duct cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
Hear when a new Advanced Cholangiocarcinoma (Part 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.